Trial Profile
A Randomized Evaluation of the Effects of Valsartan and Aliskiren in Combination Versus Tekturna Alone on Hemostatic Biomarkers in Patients With Newly Diagnosed Mild to Moderate Hypertension and Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Valsartan (Primary)
- Indications Essential hypertension
- Focus Biomarker; Pharmacodynamics
- Acronyms AVID
- 03 Apr 2010 New trial record